Shi Ming | Liver Surgery | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Shi Ming

Title: Professor, Chief physician, Doctoral supervisor, winner of the National Science Fund for Distinguished Young Scholars, Leading Medical Talents of Guangdong Province and the Leading Talents of Scientific and Technological Innovation of "Guangdong Special Support Plan"

Email: shiming@sysu.edu.cn

Phone:

Profile

Dr. Shi Ming has sufficient experience in liver cancer treatment including locoregional and systemic therapy, like surgery, interventional therapy, target therapy and immunotherapy. He has done a lot of clinical trials and fundamental research focus on optimizing the treatment of stages of B&C HCC. He has numerous publications as corresponding author in the J Clin Oncol, JAMA Oncol, J Natl Cancer Inst, Hepatology, and more. He also figured out that arterial chemotherapy is the critical factor to improve the TACE effect, and proposed a new scheme of hepatic arterial infusion chemotherapy of FOLFOX (FOLFOX-HAIC). Furthermore, he has proposed a new treatment strategy: triple combined therapy (FOLFOX-HAIC + target therapy + immunotherapy) for advanced hepatocellular carcinoma. Additionally, he has done much research to figure out novel biomarkers predicting drug resistance, and discovered a novel therapeutic target of hepatocellular carcinoma. The above research projects have been cited by six international guidelines and consensuses, including the 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights, Guidelines of Chinese society OF clinical oncology (CSCO): Hepatocellular carcinoma, Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO, EASL–EORTC Clinical Practice Guidelines: Management (2012), and Guidelines of the American Society for Interventional Radiology for Liver Cancer (2012).

Interests

Therapeutic optimization for the intermediate-advanced hepatocellular carcinoma and the mechanism of the drug resistance in hepatocellular carcinoma.

Education

Graduated from Zhongshan Medical University with a bachelor's degree in clinical medicine. Received his PhD from Sun Yat-sen University in 2005, and was a visiting scholar in Rotenberg Hospital, Diakonie, Germany for general surgery and laparoscopy from 2008 to 2009, and carried out medical research for genetic precision medical research at the National Cancer Center Singapore in 2012.

Publications

1) Li QJ#, He MK#, Chen HW#, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M*. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase 3 trial. J Clin Oncol 2021: JCO.21.00608.

2) He MK, Li QJ, Zou RH, Shen JX, Fang WQ, Tan GS, Zhou YM, Wu XP, Xu L, Wei W, Le Y, Zhou ZG, Zhao M, Guo Y, Guo RP, Chen MS, Shi M*. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5(7):953-960.

3) OuYang HY, Xu J, Luo J, Zou RH, Chen K, Le Y, Zhang YF, Wei W, Guo RP, Shi M*. MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. Hepatology 2016; 63(4): 1227-39.

4) Shi M*, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 2013;105(1):59-68.

5) Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M*. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple and resectable hepatocellular carcinoma: a prospective non-randomized analysis. Radiology 2011; 259:286-95.

6) Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ*. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007; 245:36-43.

Updated November 2021 by International Office, Sun Yat-sen University Cancer Center

Our Experts